# Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

> **NCT04205812** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 583 (actual)

## Conditions studied

- Metastatic Squamous Non-Small Cell Lung Cancer
- Metastatic Nonsquamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Retifanlimab
- **DRUG:** Placebo
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** nab-Paclitaxel

## Key facts

- **NCT ID:** NCT04205812
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-11
- **Primary completion:** 2023-12-15
- **Final completion:** 2026-08-28
- **Target enrollment:** 583 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04205812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04205812, "Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04205812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*